Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review
- PMID: 34352262
- PMCID: PMC8792149
- DOI: 10.1016/j.jid.2021.06.033
Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review
Abstract
The psychometric validity and reliability of widely used atopic dermatitis (AD) outcome measures across different races and ethnicities are unclear. We describe the rates of reporting race, ethnicity, and skin tone in studies testing the psychometric properties of AD outcome measures and compare the psychometric analyses across race, ethnicity, and skin tone. We systematically reviewed MEDLINE and EMBASE for studies reporting psychometric properties of clinician-reported or patient-reported outcome measures in AD (International Prospective Register of Systematic Reviews: CRD42021239614). Overall, 16,100 nonduplicate articles were screened; 165 met inclusion criteria. Race and/or ethnicity were reported in 55 (33.3%) studies; of those, race was assessed by self-report in 10 studies (6.1%) or was unspecified in 45 (27.3%). A total of 16 studies (9.7%) evaluated psychometric property differences by race, and only five (4.4%) of those did not recognize it as a limitation. Properties assessed across race, ethnicity, or skin tone were differential item functioning, convergent validity feasibility, inter-rater reliability, intrarater reliability, test‒retest reliability, and known-groups validity. Multiple instruments demonstrated performance differences across ethnoracial groups. This review highlights the paucity of race/ethnicity consideration for psychometric property testing in AD outcome measurement instruments. More AD outcomes instruments should be validated in diverse populations.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest:
Dr. Thyssen has been an advisor, Investigator and Speaker for Abbvie, Pfizer, LEO Pharma, Sanofi-Genzyme, Eli Lilly & Co and Regeneron. He has received grants from Sanofi-Genzyme and Regeneron.
Dr. Alexis declares Grants (funds to institution) - Leo, Novartis, Almirall, Bristol-Myers-Squibb, Amgen, Menlo, Galderma, Valeant (Bausch Health), Cara, Arcutis. Consultant/Advisory Board - Leo, Galderma, Pfizer, Sanofi-Regeneron, Dermavant, Beiersdorf, Valeant, L’Oreal, BMS, Bausch health , UCB, Vyne , Arcutis, Janssen, Allergan, Almirall, Abbvie, Sol-Gel, Amgen. Speaker - Regeneron, SANOFI-Genzyme, Pfizer, Astra Zeneca
The remaining authors state no conflict of interest.
Figures
Similar articles
-
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.Health Qual Life Outcomes. 2021 Oct 23;19(1):247. doi: 10.1186/s12955-021-01877-8. Health Qual Life Outcomes. 2021. PMID: 34688290 Free PMC article.
-
Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.J Allergy Clin Immunol. 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12. J Allergy Clin Immunol. 2013. PMID: 24035157 Review.
-
A pilot comparison study of four clinician-rated atopic dermatitis severity scales.Br J Dermatol. 2015 Aug;173(2):488-97. doi: 10.1111/bjd.13846. Epub 2015 Jul 1. Br J Dermatol. 2015. PMID: 25891151 Clinical Trial.
-
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.Br J Dermatol. 2019 Oct;181(4):761-769. doi: 10.1111/bjd.17744. Epub 2019 May 1. Br J Dermatol. 2019. PMID: 30729499 Free PMC article.
-
Assessing Response in Atopic Dermatitis: A Systematic Review of the Psychometric Performance of Measures Used in HTAs and Clinical Trials.Dermatol Ther (Heidelb). 2023 Nov;13(11):2549-2571. doi: 10.1007/s13555-023-01038-3. Epub 2023 Sep 25. Dermatol Ther (Heidelb). 2023. PMID: 37747670 Free PMC article. Review.
Cited by
-
Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver-provided photos and videos.Pediatr Dermatol. 2022 Jul;39(4):547-552. doi: 10.1111/pde.15003. Epub 2022 May 6. Pediatr Dermatol. 2022. PMID: 35522088 Free PMC article.
-
Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials.J Clin Med. 2023 Jun 1;12(11):3805. doi: 10.3390/jcm12113805. J Clin Med. 2023. PMID: 37297999 Free PMC article. Review.
References
-
- Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology 1993;186(1):23–31. - PubMed
-
- EASI for clinical signs. HOME For Eczema: HOME For Eczema; 2017.
-
- Al-Buainain H, Kholoud A, Mahmoud M, Allam M. Correlation between Quality of Life and Disease Severity in Children with Atopic Dermatitis in the State of Qatar. Panarab J;20.
-
- Al Shobaili HA. The impact of childhood atopic dermatitis on the patients' family. Pediatr Dermatol;27(6):618–23. - PubMed
-
- Alzolibani A Impact of atopic dermatitis on the quality of life of Saudi children. Saudi medical journal 2014;35(4):391–6. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous